Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.

Mun SH, Won HY, Hernandez P, Aguila HL, Lee SK.

J Bone Miner Res. 2013 Apr;28(4):948-59. doi: 10.1002/jbmr.1787.

PMID:
23044992
[PubMed - in process]
Free PMC Article
2.

Macrophage migration inhibitory factor inhibits osteoclastogenesis.

Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R, Kuchel GA, Lee SK.

Bone. 2009 Oct;45(4):640-9. doi: 10.1016/j.bone.2009.06.028. Epub 2009 Jul 7.

PMID:
19591967
[PubMed - indexed for MEDLINE]
3.

Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.

Lee SK, Kalinowski JF, Jastrzebski SL, Puddington L, Lorenzo JA.

Endocrinology. 2003 Aug;144(8):3524-31.

PMID:
12865334
[PubMed - indexed for MEDLINE]
4.

IL-1 plays an important role in the bone metabolism under physiological conditions.

Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y.

Int Immunol. 2010 Oct;22(10):805-16. doi: 10.1093/intimm/dxq431. Epub 2010 Aug 2.

PMID:
20679512
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.

Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF.

J Bone Miner Res. 2002 Jul;17(7):1200-10.

PMID:
12096833
[PubMed - indexed for MEDLINE]
7.

RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.

Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.

Bone. 2006 May;38(5):678-85. Epub 2005 Nov 23.

PMID:
16309985
[PubMed - indexed for MEDLINE]
8.

Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss.

Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA.

J Bone Miner Res. 2006 May;21(5):695-702.

PMID:
16734384
[PubMed - indexed for MEDLINE]
9.

Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF.

Cytokine. 2015 Jan 31;72(2):135-145. doi: 10.1016/j.cyto.2014.11.015. [Epub ahead of print]

PMID:
25647268
[PubMed - as supplied by publisher]
10.

T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy.

Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, Gronowicz G, Adams DJ, Aguila HL, Choi Y, Lorenzo JA.

J Bone Miner Res. 2006 Nov;21(11):1704-12.

PMID:
17002560
[PubMed - indexed for MEDLINE]
11.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
[PubMed - indexed for MEDLINE]
12.

Macrophage migration inhibitory factor down-regulates the RANKL-RANK signaling pathway by activating Lyn tyrosine kinase in mouse models.

Mun SH, Oh D, Lee SK.

Arthritis Rheumatol. 2014 Sep;66(9):2482-93. doi: 10.1002/art.38723.

PMID:
24891319
[PubMed - indexed for MEDLINE]
13.

The dectin 1 agonist curdlan regulates osteoclastogenesis by inhibiting nuclear factor of activated T cells cytoplasmic 1 (NFATc1) through Syk kinase.

Yamasaki T, Ariyoshi W, Okinaga T, Adachi Y, Hosokawa R, Mochizuki S, Sakurai K, Nishihara T.

J Biol Chem. 2014 Jul 4;289(27):19191-203. doi: 10.1074/jbc.M114.551416. Epub 2014 May 12.

PMID:
24821724
[PubMed - indexed for MEDLINE]
14.

Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.

Nagata N, Kitaura H, Yoshida N, Nakayama K.

Bone. 2003 Oct;33(4):721-32.

PMID:
14555278
[PubMed - indexed for MEDLINE]
15.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

PMID:
16059637
[PubMed - indexed for MEDLINE]
16.

Inducible nitric oxide synthase mediates bone development and P. gingivalis-induced alveolar bone loss.

Gyurko R, Shoji H, Battaglino RA, Boustany G, Gibson FC 3rd, Genco CA, Stashenko P, Van Dyke TE.

Bone. 2005 Mar;36(3):472-9.

PMID:
15777672
[PubMed - indexed for MEDLINE]
17.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

PMID:
20547767
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

PMID:
15824857
[PubMed - indexed for MEDLINE]
20.

Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro.

Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, Raisz LG.

Endocrinology. 2000 Jun;141(6):2054-61.

PMID:
10830290
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk